Switching Treatments with Secondary Progressive Multiple Sclerosis

If you’re living with secondary progressive multiple sclerosis (SPMS), you’ve probably noticed that your treatment plan isn’t a “set it and forget it” kind of thing.
It’s more like a long road trip with construction detours, weather changes, and the occasional “recalculating…” from your neurologist.
Switching treatments with SPMS can feel scary, but it can also be a smart, proactive move to protect your brain, your independence, and your quality of life.

In this guide, we’ll walk through why treatment switches happen, what options might be on the table, how neurologists think about risk and benefit, and what questions to ask when you’re considering a change.
We’ll also touch on the emotional side of switching and share real-world style experiences and tips from people navigating SPMS.

Quick reminder: This article is for education only. It can help you prepare great questions, but it can’t replace the advice of your neurologist or MS care team.

What Is Secondary Progressive Multiple Sclerosis, Really?

SPMS is a stage of multiple sclerosis that typically follows relapsing-remitting MS (RRMS). In RRMS, the immune system attacks, you have relapses, then you recover at least partially. Over time, some people move into a phase where disability gradually worsens, with or without obvious relapses. That’s SPMS.

Experts now describe SPMS using terms like “active” and “not active,” and “with progression” or “without progression.” In simple language:

• Active SPMS: You still have new relapses or new MRI lesions.
• Nonactive SPMS: No clear relapses or new lesions, but disability can still slowly worsen.

This distinction matters because most disease-modifying therapies (DMTs) target inflammationthe relapses and new lesions. That’s why treatment strategies for SPMS often depend on whether your disease is still “active” or has become more “silent” but progressive.

Why Switching Treatments Becomes Part of the SPMS Journey

When you were first diagnosed, you might have started on a DMT that made sense for RRMSsuch as interferons, glatiramer acetate, or newer oral or infusion therapies.
As the disease evolves into SPMS, the original treatment might not be the best fit anymore.

Common reasons for switching include:

• More disease activity: You’re having relapses, new lesions, or faster disability progression despite sticking to your medication.
• Side effects or risks: You and your doctor decide that the side-effect profile or infection risk has become too high for your situation.
• Life changes: Pregnancy plans, aging, new health conditions (like heart disease or cancer risk), or frequent infections can push a switch or de-escalation to a different drug.
• Insurance or access issues: Sometimes coverage rules or cost drive a change (annoying, but real).

Guidelines from organizations like the American Academy of Neurology (AAN) emphasize that starting, switching, and sometimes stopping DMTs are all normal parts of managing MSnot failures. The goal is always to balance controlling disease activity, limiting long-term disability, and minimizing serious side effects.

Signs It Might Be Time to Revisit Your SPMS Treatment Plan

You don’t need to wait for a catastrophe before asking about a switch. Red flags to bring up with your neurologist include:

• More frequent or severe relapses than in the past.
• New or enlarging MRI lesions despite being fully adherent to your medication.
• Gradual worsening of walking, balance, or hand function over 6–12 months, even without obvious relapses.
• Side effects that affect your daily life: frequent infections, liver issues, mood changes, intolerable flu-like symptoms, or infusion reactions.
• Trouble sticking to the regimen: if the dosing schedule or monitoring requirements just aren’t realistic for you long-term.

In research and clinical practice, neurologists often use a combination of relapse history, MRI changes, and disability scales (like the EDSS) to decide whether a therapy is “working well enough” or if it’s time to escalate, switch laterally to another high-efficacy therapy, or de-escalate.

What Treatment Options Are on the Table When You Switch?

There’s no single “SPMS drug,” but there are treatments with evidence in active SPMS, and many DMTs used in relapsing MS are considered for people who still show inflammatory activity in the progressive phase. The exact menu depends on where you live, your prior treatment history, and your health profile.

1. Disease-Modifying Therapies (DMTs) for Active SPMS

For people with active SPMS (relapses or new MRI lesions), continuing or switching DMTs remains a key strategy to reduce inflammatory activity and possibly slow disability progression.

Some options often discussed in the SPMS context include:

• Siponimod: An oral sphingosine-1-phosphate (S1P) receptor modulator specifically approved in the U.S. for adults with “relapsing forms of MS,” including active SPMS. Clinical trials (like EXPAND) showed reduced risk of disability progression and fewer relapses in SPMS with evidence of activity.
• High-efficacy DMTs used in relapsing MS: In some cases, drugs like ocrelizumab, cladribine, or other S1P modulators and monoclonal antibodies may be used when SPMS still behaves like highly active relapsing disease. These are chosen case-by-case, weighing benefits against infection and malignancy risks.
• Escalation vs de-escalation: If you’ve been on a moderate-efficacy therapy (like some injectables) and keep having relapses or progression, your neurologist might switch you to a high-efficacy agent. On the flip side, if you’re older, stable, and facing more treatment-related risks, de-escalating to a lower-risk therapy or stopping altogether may be discussed.

The specific choice depends on your prior medications, JCV antibody status, other medical conditions, age, pregnancy plans, and how aggressive your disease appears.

2. Symptom-Management Medications

Even if your DMT is focused on slowing down inflammation and progression, many people with SPMS still need targeted help for symptoms. These medications don’t change the course of the disease, but they can dramatically improve how you feel and function day-to-day.

• Spasticity: oral muscle relaxants; in some cases, botulinum toxin injections or intrathecal baclofen pumps.
• Pain and neuropathic pain: medications that calm overactive nerves; physical therapy helps too.
• Bladder and bowel issues: prescription meds, pelvic floor therapy, and timing strategies.
• Fatigue: energy-conservation strategies, sleep hygiene, and sometimes medications.

Switching DMTs often goes hand-in-hand with adjusting symptom medications. As disability changes, so do the tools you might need.

3. Rehabilitation, Lifestyle, and Non-Drug Therapies

When people hear “treatment switch,” they usually think “new pill or infusion.” But in SPMS, rehabilitation can be just as powerful as a prescription.

• Physical therapy: helps with strength, balance, gait training, and fall prevention.
• Occupational therapy: focuses on making everyday tasks doableadaptive tools, energy-conserving techniques, and home modifications.
• Speech and swallow therapy: important if speech or swallowing changes appear.
• Mental health support: counseling, support groups, and sometimes medications for depression or anxiety.
• Lifestyle strategies: cooling techniques, exercise tailored to your abilities, good sleep, and nutrition can all support your brain health.

Sometimes the most meaningful “switch” is a more intensive rehab program, not a different drugespecially for nonactive SPMS where inflammation is less of a driver.

How Neurologists Think Through a Treatment Switch

Behind the scenes, your neurologist is doing a complex balancing act. They’re looking at:

• Your relapse history and MRI trends.
• Your disability level and how quickly it has changed.
• Your age and other health conditions.
• Current treatment’s effectiveness and side effects.
• Risk of infections, PML, cancers, or organ damage.
• Your goals: staying employed, parenting, travel, independence, or fall prevention.

Research and guidelines outline when a treatment might be considered “not working well enough” and offer frameworks for switching to a higher or lower efficacy option. They also discuss when to consider stopping DMTs entirelyoften in older adults with long-standing nonactive SPMS and high treatment risk.

Washout vs Direct Switch

One big technical question is: Do we switch directly to the new drug or leave a gap (washout period)?

The answer depends on the specific medications:

• Some DMTs have long-lasting effects on your immune system, so neurologists might build in a washout to lower overlapping risks (like serious infections).
• Others are switched with minimal or no gap to avoid disease “rebound” or flares.

Studies and reviews discussing switching strategies emphasize tailoring timing to the drugs involved, your disease activity, and your individual risk profile. This is definitely not a do-it-yourself decision.

Risk–Benefit Balancing in Real Life

In theory, everyone wants “maximum control, minimum side effects.” In practice, there’s a trade-off:

• High-efficacy drugs may better control inflammation and reduce disability progression but can come with higher infection or malignancy risks and more intensive monitoring.
• Moderate-efficacy or platform therapies may feel safer long-term but might not be strong enough if your disease is still very active.

Newer studies on de-escalation are exploring whether people who’ve been stable for years can safely move to lower-risk therapies or extended dosing intervals without losing control of the disease. This is especially relevant as many people with MS now live long lives with the condition.

Questions to Ask Before Switching SPMS Treatments

Going into your appointment with a clear list of questions can help you leave feeling less overwhelmed and more confident. Consider asking:

• “What is the main reason you’re recommending a switch now?”
• “Is my SPMS considered active or not active? How do you know?”
• “What are we hoping this new treatment will accomplishfewer relapses, slower disability, better MRI, or something else?”
• “What are the most important risks I should understand about this new therapy?”
• “How will we monitor whether it’s working or causing problems?”
• “What will the transition look likewashout, overlap, or direct switch?”
• “What happens if this new treatment doesn’t work for me?”

Bring a notebook, a family member, or a friend if you can. SPMS is complicated, and having a second set of ears can help.

Insurance, Costs, and Access: The Un-fun Part of Switching

Let’s be honest: some treatment decisions are influenced by coverage, copays, and prior authorizations. Many DMTs for MS are expensive, and insurers often require:

• Proof of disease activity or disability progression.
• Documentation that you tried and didn’t respond well to other therapies.
• Regular follow-up and updated MRI results.

If you’re facing financial stress:

• Ask your neurologist’s office about prior authorization support and appeal letters.
• Look into manufacturer assistance programs and independent foundations that help with copays.
• Be open with your care team if you’re delaying doses or skipping appointments because of costthey may be able to help troubleshoot.

The Emotional Side of Switching Treatments

Switching treatments doesn’t just change your medication list; it can stir up a lot of feelings:

• Grief: acknowledging that your disease has changed or progressed.
• Fear: of new side effects, infusions, or “what if this doesn’t work either?”
• Hope: that a different approach could stabilize things, slow progression, or improve daily life.

It’s okay to feel all of this at once. Talking with a therapist, social worker, or MS support group can normalize those emotions and give you coping tools. Your neurologist cares about how you feelnot just what your MRI looks like.

Experiences and Practical Tips from People Living with SPMS

While everyone’s journey with SPMS is different, certain themes tend to show up again and again when people talk about switching treatments.
The following are composite, illustrative examples based on common experiencesnot stories from any specific individual.

“I Thought Switching Meant I Had Failed”

One common feeling is a sense of failure: “If I have to switch, does that mean I did something wrong?”
Many people start on a first-line therapy in their 20s or 30s, do well for a while, and then notice their walking or balance slowly changing as they move into SPMS.
When the neurologist brings up switching to a different DMTor sometimes de-escalating or stoppingpeople may interpret that as a personal failure.

Over time, though, many patients come to see switching as a sign of active management, not failure.
Just like you might change blood pressure medications if the first one isn’t ideal, changing MS treatments is part of adapting to new information.
SPMS is dynamic; your treatment plan is allowed to be dynamic too.

“The Transition Period Was the Hardest Part”

Another frequent theme is that the most stressful time isn’t actually being on the new drugit’s the transition in between.
People worry: “Will my disease flare during the washout?” “What if I catch an infection during the switch?” “What if I regret this?”

Practical strategies that many find helpful include:

• Scheduling the switch strategically: choosing a time when work, caregiving, or school demands are a bit lighter.
• Asking for a clear written plan: exact dates or time frames for stopping one therapy, starting another, and doing blood tests or MRIs.
• Building a “support calendar”: arranging help with rides, meals, or childcare around infusion days or the first weeks on a new oral therapy.
• Having a symptom diary: jotting down fatigue, mobility, and mood changes to bring to follow-up visits.

People often report that once they’re a few months into the new regimen and past the “unknown,” anxiety starts to easeespecially if relapses stay quiet and they feel more stable.

“Rehab Turned Out to Be as Important as the New Drug”

Many individuals with SPMS say that the biggest functional gains didn’t necessarily come from the new medication alone, but from pairing it with a renewed focus on rehabilitation.
For example, someone who switched to a therapy appropriate for active SPMS might also commit to:

• Weekly physical therapy focused on gait and core strength.
• Occupational therapy to reorganize their home and workspace for less fatigue.
• Energy management strategies to avoid the “crash” that follows pushing too hard.

Over several months, these changes can translate into fewer falls, more confidence in walking, and the ability to keep working or staying socially engagedeven if some disability remains.

“We Had to Re-Negotiate What ‘Successful Treatment’ Means”

Another emotional shift comes when people and their care teams redefine what “success” looks like in SPMS. In RRMS, success might mean “no relapses and no new MRI lesions.”
In SPMS, especially nonactive SPMS, success might look more like:

• Slower progression, rather than no progression at all.
• Less fatigue or better ability to participate in important activities.
• Fewer infections or hospitalizations, especially if de-escalating from a high-risk therapy.

Patients often say that having honest conversations about realistic goalsmaintaining independence as long as possible, staying safe, and prioritizing what truly matters day-to-dayhelps them feel more in control, even as the disease changes.

“Advocating for Myself Made a Huge Difference”

Many people with SPMS who’ve gone through multiple treatment switches describe a turning point when they started treating themselves as an active partner rather than a passive passenger. That might mean:

• Bringing written questions to every appointment.
• Asking to see their MRI images and having the neurologist explain any changes in simple language.
• Requesting referrals to rehab, counseling, or social work instead of waiting for someone to suggest them.
• Being honest about their ability to follow complex dosing schedules or monitoring plans.

This kind of self-advocacy doesn’t guarantee a perfect outcomenothing in MS is guaranteedbut it often leads to treatment plans that fit better with real life, and that can make a big difference in long-term well-being.

Putting It All Together

Switching treatments with secondary progressive multiple sclerosis is not a sign that you’ve failed; it’s a reflection of how complex and evolving MS really is.
As the disease changes, it’s reasonableand often wiseto update your strategy. That might mean moving to a therapy designed for active SPMS, adjusting to a safer option when risks rise, or focusing more on rehab and symptom management when inflammation quiets down but progression continues.

The best switch is one made thoughtfully: grounded in evidence, guided by your neurologist’s expertise, and aligned with your own values and goals.
Ask questions, bring support, and remember that your experience and preferences are central to every decision.

You’re not just “on” a treatment; you’re leading a lifeand your treatment plan should help you live that life as fully and safely as possible.